Table 2. Selection of ongoing clinical trials evaluating epigenetic targeted therapies in hematologic malignancies.
Clinical Trial | Intervention | Malignancy studied |
---|---|---|
EZH2 inhibitors | ||
NCT02395601 | Phase 1 Study: EZH2 inhibitor CPI-1205 | Progressive B-cell lymphomas |
NCT01897571 | Phase 1/2 Study: EZH2 inhibitor E7438 | B-cell lymphomas and advanced solid tumors |
KDM inhibitors | ||
NCT02261779 | Phase 1/2 Study: ATRA + tranylcypromine (TCP) an irreversible monoamine-oxidase (MAO) and Lysin-specific demethylase (LSD) inhibitor | Relapsed/refractory AML |
IDH2 inhibitors | ||
NCT01915498 | Phase 1/2 Study: reversible inhibitor of mutant IDH2 AG-221 | Advanced hematologic malignancies with IDH2 mutation |
NCT02273739 | Phase 1/2 Study: reversible inhibitor of mutant IDH2 AG-221 | Advanced solid tumors (glioma) and angioimmunoblastic T-cell lymphoma |
BET1/DOT1L inhibitors | ||
NCT01943851 | Phase 1/2 Study: BET inhibitor GSK525762 | Relapsed/refractory hematologic malignancies (leukemias, myeloproliferative neoplasms, lymphomas, and myelomas) |
NCT02158858 | Phase 1 Study: BET inhibitor CPI-0610 | AML, myelodysplastic syndromse, myeloproliferative neoplasms, myelofibrosis |
NCT02308761 | Phase 1 Study: BET inhibitor TEN-010 | AML, myelodysplastic syndromse |
NCT01684150 | Phase 1 Study: second generation DOT1L inhibitor EPZ-5676 | AML/ALL/MLL with MLL1 rearrangements (including 11q23 or partial tandem duplications) in adult patients |
NCT02141828 | Phase 1 Study: second generation DOT1L inhibitor EPZ-5676 | AML/ALL with MLL1 rearrangements (including 11q23 or partial tandem duplications) in pediatric patients |
Combination treatment with cancer vaccines | ||
NCT01483274 | Phase 1 study: Decitabine + donor lymphocyte infusion + Vaccine (autologous dendritic cells) | AML with relapse after allogeneic stem cell transplantation |
Combination treatment with immune checkpoint inhibitors | ||
NCT02281084 | Phase 2 Study: Durvalumab (PD-L1 inhibitor) + CC-486 (oral azacitidine) | Myelodysplastic syndromes |
NCT02530463 | Phase 2 Study: Nivolumab (PD-1 inhibitor) and/or Ipilimumab (CTLA-4 inhibitor) + azacitidine | Myelodysplastic syndromes |
This list is not complete but presents a selection of clinical trials by the authors of this manuscript meant to illustrate the different strategies.